Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-667: Pembrolizumab in Children and Young Adults With Newly Diagnosed Classical Hodgkin Lymphoma
NCT03407144Phase 2Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Apr 2018
- Primary completion
- Feb 2027
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 16
01
Overview
A Phase 2 trial of pembrolizumab in classical Hodgkin lymphoma (cHL), sponsored by Merck & Co.. Started Apr 2018; status: active, not recruiting.
02
Drugs
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on NCT03407144.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03407144.